Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactitol plus GnP for unresectable advanced pancreatic cancer
jRCTs041250217Recruiting
- Sponsor
- National Hospital Organization
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lactitol, gemcitabine and paclitaxel in pancreatic cancer (PC), sponsored by National Hospital Organization. Primary endpoint: Response rate at 3 months. Started Mar 2026; status: recruiting.
02
Drugs
lactitolgemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041250217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250217.